Shanghai Fosun Pharmaceutical (SHA:600196) said its two newly established venture capital funds have completed filing with the Asset Management Association of China, effective July 28.
The Tianjin Phase II Fund, with a group investment of 29.8 million yuan, and the Hangzhou Fund, with a group investment of 27.8 million yuan, are both managed by Shanghai Fujian Equity Investment Fund Management.
The funds aim to expand Shanghai Fosun Pharmaceutical's pipeline of early-stage innovative projects in pharmaceuticals and medical devices.